Novan Inc
F:6LUA

Watchlist Manager
Novan Inc Logo
Novan Inc
F:6LUA
Watchlist
Price: 0.001 EUR Market Closed
Market Cap: 1.3k EUR

Novan Inc
Accrued Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Novan Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Novan Inc
F:6LUA
Accrued Liabilities
$18.8m
CAGR 3-Years
71%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Accrued Liabilities
$32.9B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
10%
Bristol-Myers Squibb Co
NYSE:BMY
Accrued Liabilities
$15B
CAGR 3-Years
15%
CAGR 5-Years
11%
CAGR 10-Years
16%
Pfizer Inc
NYSE:PFE
Accrued Liabilities
$3B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Accrued Liabilities
$16B
CAGR 3-Years
5%
CAGR 5-Years
7%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Accrued Liabilities
$19.6B
CAGR 3-Years
27%
CAGR 5-Years
25%
CAGR 10-Years
19%
No Stocks Found

Novan Inc
Glance View

Market Cap
1.3k EUR
Industry
Pharmaceuticals

Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.

6LUA Intrinsic Value
Not Available

See Also

What is Novan Inc's Accrued Liabilities?
Accrued Liabilities
18.8m USD

Based on the financial report for Dec 31, 2022, Novan Inc's Accrued Liabilities amounts to 18.8m USD.

What is Novan Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
27%

Over the last year, the Accrued Liabilities growth was 277%. The average annual Accrued Liabilities growth rates for Novan Inc have been 71% over the past three years , 27% over the past five years .

Back to Top